Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.
Paul M. Barr, MD, an associate professor of medicine and director of the Clinical Trials Office at the Wilmot Cancer Institute of the University of Rochester Medical Center, discusses the next steps with the combination of umbralisib (Ukoniq), ublituximab, and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
During the 2020 ASH Annual Meeting and Exposition, findings from a phase 1/2 study demonstrated a 100% objective response rate with umbralisib/ublituximab/venetoclax in 27 patients with relapsed/refractory CLL at cycle 12.
The trial gave rise to the ongoing phase 2 ULTRA-V trial (NCT03801525), which is evaluating the same regimen in patients with CLL but will be administered over 2 years vs 1 year, says Barr. Additionally, patients are not required to have received prior therapy for CLL, Barr explains.
Taken collectively, the data from these studies will shed light on the utility of 1- and 2-year courses of the triplet regimen with regard to efficacy and safety, concludes Barr.